UM
TEVA icon

UniSuper Management’s Teva Pharmaceuticals TEVA Stock Holding History

UniSuper Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
32,375
+9,175
+40% +$306K 0.01% 499
2026
Q1 		$699K Hold
23,200
– – ﹤0.01% 563
2025
Q4 		$724K Sell
23,200
-10,125
-30% -$249K ﹤0.01% 565
2025
Q3 		$673K Buy
33,325
+14,225
+74% +$250K ﹤0.01% 583
2025
Q2 		$320K Sell
19,100
-2,600
-12% -$42K ﹤0.01% 642
2025
Q1 		$334K Hold
21,700
– – ﹤0.01% 645
2024
Q4 		$478K Sell
21,700
-287,473
-93% -$5.23M ﹤0.01% 594
2024
Q3 		$5.57M Buy
309,173
+282,773
+1,071% +$4.95M 0.04% 213
2024
Q2 		$429K Buy
26,400
+10,500
+66% +$162K ﹤0.01% 821
2024
Q1 		$224K Buy
15,900
+8,300
+109% +$105K ﹤0.01% 918
2023
Q4 		$79.3K Hold
7,600
– – ﹤0.01% 668
2023
Q3 		$77.5K Hold
7,600
– – ﹤0.01% 644
2023
Q2 		$57.2K Buy
+7,600
New +$61.6K ﹤0.01% 690

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

UniSuper Management's TEVA Position: Q2 2026 in Review

UniSuper Management increased its Teva Pharmaceuticals (TEVA) stake by 40% in Q2 2026, buying an estimated $306K and bringing the position to 32,375 shares worth $1.1M. The position accounts for 0.01% of the portfolio, ranked #499.

UniSuper Management first reported a position in TEVA in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.57M in Q3 2024. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • UniSuper Management held 32,375 shares of Teva Pharmaceuticals worth $1.1M as of Q2 2026.
  • UniSuper Management bought 9,175 Teva Pharmaceuticals shares in Q2 2026, an estimated $306K.
  • Teva Pharmaceuticals made up 0.01% of UniSuper Management's portfolio in Q2 2026, its #499 holding.
  • UniSuper Management first reported a position in Teva Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • UniSuper Management's Teva Pharmaceuticals position peaked at $5.57M in Q3 2024.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on UniSuper Management's 13F filing for Q2 2026, filed 14 Aug 2026.